Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 287

Results For "Global"

4838 News Found

Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%
Drug Approval | August 17, 2023

Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%

Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace


Lupin Launches Tiotropium Dry Powder for Inhaler for COPD in US
News | August 17, 2023

Lupin Launches Tiotropium Dry Powder for Inhaler for COPD in US

Lupin actively contributes to alleviating the burden of COPD for patients across the nation


BioNTech appointing James Ryan as Chief Legal Officer
People | August 16, 2023

BioNTech appointing James Ryan as Chief Legal Officer

Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry


Cipla launches knowledge sharing platform ‘Ciplamed 2.0’
Digitisation | August 16, 2023

Cipla launches knowledge sharing platform ‘Ciplamed 2.0’

CiplaMed 2.0 leverages advanced analytics and automation


Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations
Drug Approval | August 16, 2023

Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations

The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.


Lupin gets USFDA approval for Doxycycline Hyclate Delayed-Release Tablets USP
Drug Approval | August 16, 2023

Lupin gets USFDA approval for Doxycycline Hyclate Delayed-Release Tablets USP

Doxycycline Hyclate Delayed-Release Tablets USP (RLD Doryx ) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT June 2023).


CrisprBits collaborates with Molbio Diagnostics to launch CRISPR-based Point-of-Care tests
Clinical Trials | August 16, 2023

CrisprBits collaborates with Molbio Diagnostics to launch CRISPR-based Point-of-Care tests

CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions


Pfizer receives USFDA approval for Elrexfio for the treatment of relapsed or refractory multiple myeloma
Drug Approval | August 16, 2023

Pfizer receives USFDA approval for Elrexfio for the treatment of relapsed or refractory multiple myeloma

ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity


Exor to buy 15% shareholding in Philips
News | August 16, 2023

Exor to buy 15% shareholding in Philips

Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases


WuXi XDC and Boostimmune sign MoU for integrated services
News | August 13, 2023

WuXi XDC and Boostimmune sign MoU for integrated services

Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform